Product Profiles: Top 20 Oncology Therapy Brands 2011-21Report Details:Published:September 2012No. of Pages: 157Price: Sin...
•In depth assessment of each brand’s clinical and commercial attractiveness, including Datamonitor’s drug assessment chart...
Product positioningTop 20 positionClinical and commercial attractivenessRevlimid (lenalidomide; Celgene)Drug profileDevelo...
Product positioningTop 20 positionClinical and commercial attractivenessTarceva (erlotinib; OSI Pharmaceuticals/Genentech/...
Product positioningTop 20 positionClinical and commercial attractivenessFemara (letrozole; Novartis/Chugai)Drug profileDev...
WebsitesRevlimidJournal papersWebsitesAlimtaJournal papersWebsitesLupronWebsitesOtherEloxatinJournal papersWebsitesErbitux...
TasignaWebsitesTemodarJournal papersWebsitesAppendixJournal papersWebsitesOtherAPPENDIXMarket definition for cancer therap...
Table: Xeloda (capecitabine; Roche/Genentech/Chugai) – drug profile, 2012Table: Overview of pivotal trial data for Xeloda,...
2012Figure: Datamonitors drug assessment summary of Revlimid (lenalidomide; Celgene), 2012Figure: Alimta’s SWOT analysis f...
Figure: Datamonitor’s drug assessment summary for Sutent (sunitinib; Pfizer) in cancer, 2012Figure: Datamonitors drug asse...
Upcoming SlideShare
Loading in …5
×

Product Profiles: Top 20 Oncology Therapy Brands 2011-21

298 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
298
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Product Profiles: Top 20 Oncology Therapy Brands 2011-21

  1. 1. Product Profiles: Top 20 Oncology Therapy Brands 2011-21Report Details:Published:September 2012No. of Pages: 157Price: Single User License – US$11400The high level of commercial success experienced by the key companies in the oncology marketmakes it extremely attractive to drug developers. The treatment of cancer has shifted away frommass market blockbuster cytotoxic drugs toward a more personalized therapy approach. However,government austerity packages could see slower commercial growth and larger generic erosion ofkey brands.Features and benefits•Assess detailed drug information for the leading oncology brands, including detailed clinical trial information for each approved indication•Understand the key factors that led to the success of the top 20 oncology therapy brands and the obstacles that they have encountered•Gain insight into the clinical and commercial attractiveness for each of the branded drugs and how this will affect their future salesHighlightsTargeted therapies comprise 60% of the top 20 brands in 2011 with Roche’s monoclonal antibodyfranchise maintaining the top three positions. A potential to demonstrate improved clinical efficacywith reduced off-target toxicity, combined with an ability to demand higher prices, makes this drugclass clinically and commercially attractive.An aging cytotoxic market means that cytotoxic brands are becoming less commercially attractive.In the past few years many of the blockbuster cytotoxics have come off-patent and now facegeneric erosion. As developers turn their attention toward new targeted therapies the number ofnew cytotoxics entering the market has decreased.Antihormonal therapies have high clinical attractiveness, but despite strong sales they are limitedto two indications. Effective lifecycle management has ensured that sales remain high despitepatent expiries in almost every major market.Your key questions answered•Product profiles and development overviews detailing companies involved and the key clinical data leading to each approval•Overview of brand positioning in marketed indications relative to competitors and in terms of ability to meet unmet needs•SWOT analysis of each brand in the seven major market top 20
  2. 2. •In depth assessment of each brand’s clinical and commercial attractiveness, including Datamonitor’s drug assessment chartsGet your copy of this report @http://www.reportsnreports.com/reports/195675-product-profiles-top-20-oncology-therapy-brands-2011-21.htmlMajor points covered in Table of Contents of this report includeTable of ContentsOVERVIEWCatalystSummaryEXECUTIVE SUMMARYStrategic scoping and focusDatamonitor key findingsPRODUCT OVERVIEWTop 20 branded productsDatamonitor’s assessment summaryMARKETED PRODUCT PROFILESAvastin (bevacizumab; Genentech/Roche/Chugai)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessRituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessDrug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessGleevec (imatinib; Novartis)Drug profileDevelopment overviewSWOT analysis
  3. 3. Product positioningTop 20 positionClinical and commercial attractivenessRevlimid (lenalidomide; Celgene)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessAlimta (pemetrexed; Eli Lilly)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessLupron (leuprolide; Takeda/Abbott)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessEloxatin (oxaliplatin; Sanofi/Yakult Honsha)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessErbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessVelcade (bortezomib; Takeda/Johnson & Johnson)Drug profileDevelopment overviewSWOT analysis
  4. 4. Product positioningTop 20 positionClinical and commercial attractivenessTarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche/Chugai)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessXeloda (capecitabine; Roche/Genentech/Chugai)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessNexavar (sorafenib; Bayer Schering/Onyx)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessTaxotere (docetaxel; Sanofi)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessSutent (sunitinib; Pfizer)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessSprycel (dasatinib; Bristol-Myers Squibb)Drug profileDevelopment overviewSWOT analysis
  5. 5. Product positioningTop 20 positionClinical and commercial attractivenessFemara (letrozole; Novartis/Chugai)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessZoladex (goserelin; AstraZeneca)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessTasigna (nilotinib; Novartis)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessTemodar (temozolomide; Merck & Co.)Drug profileDevelopment overviewSWOT analysisProduct positioningTop 20 positionClinical and commercial attractivenessBIBLIOGRAPHYAvastinJournal papersWebsitesRituxanWebsitesHerceptinJournal papersWebsitesGleevecJournal papers
  6. 6. WebsitesRevlimidJournal papersWebsitesAlimtaJournal papersWebsitesLupronWebsitesOtherEloxatinJournal papersWebsitesErbituxJournal papersWebsitesVelcadeJournal papersWebsitesTarcevaWebsitesXelodaJournal papersWebsitesNexavarJournal papersWebsitesTaxotereWebsitesSutentJournal papersWebsitesSprycelJournal papersWebsitesFemaraJournal papersWebsitesZoladexJournal papersWebsitesOther
  7. 7. TasignaWebsitesTemodarJournal papersWebsitesAppendixJournal papersWebsitesOtherAPPENDIXMarket definition for cancer therapiesAntihormonal therapies by ATC classCytotoxic therapies by ATC classTargeted therapies by ATC classDatamonitor drug assessment scorecardContributing expertsConferences attendedList of TablesTable: Drugs included in the top 20 cancer therapy brands ranked according to company-reportedsales in the seven major markets, 2011Table: Avastin (bevacizumab; Roche/Chugai) – drug profile, 2012Table: Overview of pivotal trial data for Avastin in cancer, 2012Table: Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo) – drug profile, 2012Table: Overview of pivotal trial data for Rituxan in cancer, 2012Table: Herceptin (trastuzumab; Roche/Chugai) – drug profile, 2012Table: Overview of pivotal trial data for Herceptin in cancer, 2012Table: Gleevec (imatinib; Novartis) – drug profile, 2012Table: Overview of pivotal trial data for Gleevec in cancer, 2012Table: Revlimid (lenalidomide; Celgene) – drug profile, 2012Table: Overview of pivotal trial data for Revlimid in cancer, 2012Table: Alimta (pemetrexed; Eli Lilly) – drug profile, 2012Table: Overview of pivotal trial data for Alimta, 2012Table: Lupron (leuprolide; Takeda/Abbott) – drug profile, 2012Table: Overview of pivotal trial data for Lupron, 2012Table: Eloxatin (oxaliplatin; Sanofi/Yakult Honsha) – drug profile, 2012Table: Overview of pivotal trial data for Eloxatin, 2012Table: Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) – drug profile, 2012Table: Overview of pivotal trial data for Erbitux in cancer, 2012Table: Velcade (bortezomib; Takeda/Johnson & Johnson) – drug profile, 2012Table: Overview of main pivotal trial data for Velcade in cancer, 2012Table: Tarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche) – drug profile, 2012Table: Overview of pivotal trial data for Tarceva in cancer, 2012
  8. 8. Table: Xeloda (capecitabine; Roche/Genentech/Chugai) – drug profile, 2012Table: Overview of pivotal trial data for Xeloda, 2012Table: Nexavar (sorafenib; Bayer Schering/Onyx) – drug profile, 2012Table: Overview of pivotal trial data for Nexavar in cancer, 2012Table: Taxotere (docetaxel; Sanofi) – drug profile, 2012Table: Overview of pivotal trial data for Taxotere, 2012Table: Sutent (sunitinib; Pfizer) – drug profile, 2012Table: Overview of pivotal trial data for Sutent in cancer, 2012Table: Sprycel (dasatinib; Bristol-Myers Squibb) – drug profile, 2012Table: Overview of pivotal trial data for Sprycel in cancer, 2012Table: Femara (letrozole; Novartis/Chugai) – drug profile, 2012Table: Overview of pivotal trial data for Femara, 2012Table: Zoladex (goserelin; AstraZeneca) – drug profile, 2012Table: Overview of pivotal trial data for Zoladex, 2012Table: Tasigna (nilotinib; Novartis) – drug profile, 2012Table: Overview of pivotal trial data for Tasigna in cancer, 2012Table: Temodar (temozolomide; Merck & Co.) – drug profile, 2012Table: Overview of pivotal trial data for Temodar, 2012Table: Definition of the cancer market, 2012Table: Datamonitor’s drug assessment parameters for key oncology therapiesList of FiguresFigure: Datamonitors drug assessment summary of the top 20 oncology therapy brands, 2012Figure: Avastin – SWOT analysis in cancer, 2012Figure: Datamonitor’s drug assessment summary for Avastin (bevacizumab;Genentech/Roche/Chugai) in cancer, 2012Figure: Datamonitors drug assessment summary of Avastin (bevacizumab;Genentech/Roche/Chugai), 2012Figure: Rituxan – SWOT analysis in cancer, 2012Figure: Datamonitor’s drug assessment summary for Rituxan (rituximab; BiogenIdec/Roche/Chugai/Zenyaku Kogyo) in cancer, 2012Figure: Datamonitors drug assessment summary of Rituxan (rituximab; BiogenIdec/Roche/Chugai/Zenyaku Kogyo), 2012Figure: Herceptin – SWOT analysis in cancer, 2012Figure: Datamonitor’s drug assessment summary for Herceptin (trastuzumab; Roche/Chugai) incancer, 2012Figure: Datamonitors drug assessment summary of Herceptin (trastuzumab;Genentech/Roche/Chugai), 2012Figure: Gleevec – SWOT analysis in cancer, 2012Figure: Datamonitor’s drug assessment summary for Gleevec (imatinib; Novartis) in cancer, 2012Figure: Datamonitors drug assessment summary of Gleevec (imatinib; Novartis), 2012Figure: Revlimid – SWOT analysis in cancer, 2012Figure: Datamonitor’s drug assessment summary for Revlimid (lenalidomide; Celgene) in cancer,
  9. 9. 2012Figure: Datamonitors drug assessment summary of Revlimid (lenalidomide; Celgene), 2012Figure: Alimta’s SWOT analysis for cancer, 2012Figure: Datamonitors drug assessment summary of Alimta (pemetrexed; Eli Lilly), 2012Figure: Datamonitor drug assessment summary of Alimta (pemetrexed; Eli Lilly) , 2012Figure: Lupron’s SWOT analysis for cancer, 2012Figure: Datamonitors drug assessment summary of Lupron (leuprolide; Takeda/Abbott), 2012Figure: Datamonitor drug assessment summary of Lupron (leuprolide; Takeda/Abbott) , 2012Figure: Eloxatin’s SWOT analysis for cancer, 2012Figure: Datamonitors drug assessment summary of Eloxatin (oxaliplatin; Sanofi/Yakult Honsha),2012Figure: Datamonitor drug assessment summary of Eloxatin (oxaliplatin; Sanofi/Yakult Honsha) ,2012Figure: Erbitux – SWOT analysis in cancer, 2012Figure: Datamonitor’s drug assessment summary for Erbitux (cetuximab; Eli Lilly/Bristol-MyersSquibb/Merck KGaA) in cancer, 2012Figure: Datamonitors drug assessment summary of Erbitux (cetuximab; Eli Lilly/Bristol-MyersSquibb/Merck KGaA), 2012Figure: Velcade – SWOT analysis in cancer, 2012Figure: Datamonitor’s drug assessment summary for Velcade (bortezomib; Takeda/Johnson &Johnson) in cancer, 2012Figure: Datamonitors drug assessment summary of Velcade (bortezomib; Takeda/Johnson &Johnson), 2012Figure: Tarceva – SWOT analysis in cancer, 2012Figure: Datamonitor’s drug assessment summary for Tarceva (erlotinib; OSIPharmaceuticals/Genentech/Roche) in cancer, 2012Figure: Datamonitors drug assessment summary of Tarceva (erlotinib; OSIPharmaceuticals/Genentech/Roche), 2012Figure: Xeloda’s SWOT analysis for cancer, 2012Figure: Datamonitors drug assessment summary of Xeloda (capecitabine;Roche/Genentech/Chugai), 2012Figure: Datamonitor drug assessment summary of Xeloda (capecitabine;Roche/Genentech/Chugai) , 2012Figure: Nexavar – SWOT analysis in cancer, 2012Figure: Datamonitor’s drug assessment summary for Nexavar (sorafenib; Bayer Schering/Onyx) incancer, 2012Figure: Datamonitors drug assessment summary of Nexavar (sorafenib; Bayer Schering/Onyx),2012Figure: Taxotere’s SWOT analysis for cancer, 2012Figure: Datamonitors drug assessment summary of Taxotere (docetaxel; Sanofi), 2012Figure: Datamonitor drug assessment summary of Taxotere (docetaxel; Sanofi) , 2012Figure: Sutent – SWOT analysis in cancer, 2012
  10. 10. Figure: Datamonitor’s drug assessment summary for Sutent (sunitinib; Pfizer) in cancer, 2012Figure: Datamonitors drug assessment summary of Sutent (sunitinib; Pfizer), 2012Figure: Sprycel – SWOT analysis in cancer, 2012Figure: Datamonitor’s drug assessment summary for Sprycel (dasatinib; Bristol-Myers Squibb) incancer, 2012Figure: Datamonitors drug assessment summary of Sprycel (dasatinib; Bristol-Myers Squibb),2012Figure: Femara’s SWOT analysis for cancer, 2012Figure: Datamonitors drug assessment summary of Femara (letrozole; Novartis/Chugai), 2012Figure: Datamonitor drug assessment summary of Femara (letrozole; Novartis/Chugai) , 2012Figure: Zoladex’s SWOT analysis for cancer, 2012Figure: Datamonitors drug assessment summary of Zoladex (goserelin; AstraZeneca), 2012Figure: Datamonitor drug assessment summary of Zoladex (goserelin; AstraZeneca) , 2012Figure: Tasigna – SWOT analysis in cancer, 2012Figure: Datamonitor’s drug assessment summary for Tasigna (nilotinib; Novartis) in cancer, 2012Figure: Datamonitors drug assessment summary of Tasigna (nilotinib; Novartis), 2012Figure: Temodar’s SWOT analysis for cancer, 2012Figure: Datamonitors drug assessment summary of Temodar (temozolomide; Merck & Co.), 2012Figure: Datamonitor drug assessment summary of Temodar (temozolomide; Merck & Co.) , 2012Contact: sales@reportsandreports.com for more information.

×